After establishing the benign nature of a gastric ulcer, the treatment is primarily medical. This medical therapy is aimed to alleviate symptoms, to heal the ulcer and to prevent relapses. Based on the history of non-steroidal anti-inflammatory drugs (NSAIDs) and the Helicobacter pylori-status, gastric ulcer patients can be divided into four categories (1) 
INTRODUCTION
Histamine-2 receptor antagonists (H2RAs)b have been the mainstay of treatment of gastric ulcer for many years [1] . These compounds have proved to be more effective than antacids without relevant side-effects. H2RAs not only accelerate healing of gastric ulcer but also prevent recurrences when used as prophylactic maintenance therapy [1, 2] . However, an analysis from Scandinavia showed that even between 1980 and 1990, about one-third of gastric ulcer patients were burdened by their disease [3] . Recent developments have challenged the primacy of H2RA in the treatment of peptic lesions. First, the development of proton pump inhibitors with potent and long-acting antisecretory effects has led to higher healing rates than those obtained with H2RAs [4, 5] . Second, the discovery of the role of Helicobacter pylori infection has warranted antimicrobial therapy as the logical approach to gastric ulcer disease [6, 7] . Third, there is increasing interest in the importance of non-steroidal anti-inflammatory drugs (NSAIDs) in the pathogenesis of gastric ulcer and in the possibility of prevention with prostaglandin analogues [8, 9, 10] .
Not only antisecretory drugs but also compounds that do not interfere with gastric acid secretion have been shown to accelerate gastric ulcer healing when compared with placebo treatment [ 1] [12] . However, none of these drugs is superior to H2RAs in healing gastric ulcer and alleviating its symptoms [13] . ANTISECRETORY THERAPY IN GASTRIC ULCER Meta-analysis of various antisecretory therapies for gastric ulcer has shown that there are three primary determinants of gastric ulcer healing: (1) the duration of treatment, (2) the degree of acid suppression and (3) the duration of acid suppression over the 24-hour period [14] . The duration of treatment appears to be the most important single determinant of gastric ulcer healing. Maintaining the gastric pH above 3 for 18 hours daily predicts healing in 100 percent of gastric ulcers at eight weeks, while such a degree of acid suppression will heal all duodenal ulcers within four weeks [1, 14] . Thus, gastric ulcers require longer antisecretory therapy than duodenal ulcers.
The importance of the degree and duration of suppression of gastric acid has been clinically demonstrated in several studies comparing proton pump inhibitors with H2RAs. In a large multicentral study of 602 patients with gastric ulcer, both omeprazole 20 mg every morning and omeprazole 40 mg every morning induced significantly higher healing rates at four weeks (69 percent and 80 percent ) and eight weeks (89 percent and 96 percent) than ranitidine 150 mg twice daily (59 percent and 85 percent at four and eight weeks) [15] . Similar high healing rates were obtained with other proton pump inhibitors. With lansoprazole in doses of 15, 30 and 60 mg every morning, healing rates of gastric ulcer were 65 percent, 58 percent and 53 percent at four weeks and 92 percent, 97 percent and 93 percent at eight weeks, respectively [16] . The overall healing rates of gastric ulcer with pantoprazole were 84 percent and 97 percent at four and eight weeks, respectively [5] . When compared to H2RAs, proton pump inhibitors tend to give slightly faster symptom relief but the difference only rarely achieves statistical significance [5, 15] .
Antisecretory agents are also efficacious in the prophylaxis of gastric ulcer. This preventive effect has mainly been studied using maintenance therapy with ranitidine. In a retrospective study on patients taking 150 or 300 mg/day ranitidine as maintenance treatment for gastric ulcer prophylaxis, the cumulative remission rates were 97 percent after one year, 94 percent after two years, 90 percent after three years, 79 percent after four and five years [2] . However, since the recognition of the important role of H. pylori eradication in prevention of peptic ulcer, maintenance therapy for the prevention of gastric ulcer is likely to be replaced by H. pylori eradication regimens in the near future.
HELICOBACTER PYLORI ERADICATION IN GASTRIC ULCER Prevalence of H. pylori in gastric ulcer
It has been known for long time that gastric ulcer is often accompanied by chronic gastritis. Prostaglandin deficiency secondary to this gastritis may contribute to the development of gastric ulcer despite the absence of gastric acid hypersecretion in this condition [17] . In fact, most patients with benign gastric ulcer have normal or low gastric acid secretion. Gastric H. pylori infection may play a crucial role in the pathogenesis of the chronic inflammation of the gastric mucosa often found in gastric ulcer patients [18] . In the past 10 years, a large number of studies have been performed to determine the prevalence of H. pylori infection in gastric ulcer disease. In an analysis of 25 studies comprising 1395 patients with gastric ulcer, the prevalences of H. pylori ranged from 44 to 100 percent with an average of 84 percent [19] . In four of the studies, which comprised a total of 235 patients, the prevalence of H. pylori positivity in gastric ulcer was even100 percent The failure to find H. pylori positivity in all gastric patients may be related to the inclusion of gastric ulcer due to NSAIDs or malignancy or to the low sensitivity of the biopsy test for H. pylori [19] [23] . Endoscopy at five weeks showed complete healing of the ulcers in 84 percent on triple therapy and 73 percent on omeprazole. However, the patients treated by omeprazole had experienced less days with pain than the patients treated by triple therapy both in the first week (1.9 + 2.6 vs. 3.6 ± 3.0; p < .005) and in week two through five (4.4 +8.7 vs 7.6 + 9.5; p = .09) [23] . Thus, the combination of a proton pump inhibitor and at least two antibiotics seems presently to be the preferred therapy for H. pylorn positive gastric ulcer, since this regimen is likely to result in early pain relief and successful H. pylori eradication. Prevention ofH. pylori-positive gastric ulcers As mentioned earlier, maintenance therapy with ranitidine prevents relapse of gastric ulcer in the majority of patients [2] . In an open study with 150 or 300 mg/day ranitidine, the proportion of patients remaining free from symptomatic recurrence was 97 percent after one year and 79 percent after five years [2] . However, in a placebo-controlled study on 12-month maintenance therapy with 150 mg ranitidine at night, only 64 percent of those on ranitidine and 24 percent of those on placebo were free from gastric ulcer relapse [24] . Thus, despite maintenance therapy with ranitidine, about one-third of the patients had symptomatic or asymptomatic recurrences of gastric ulcer within one year. The recognition of the association of H. pylori infection with gastritis and peptic ulcer has prompted several studies to be performed in order to determine whether H. pylori eradication prevents relapse of gastric ulcer. Although the follow-up period was usually limited to one year at the most, several studies have confirmed the importance of H. pylori eradication therapy for prevention of gastric ulcer relapse. Graham et al. studied 15 patients with gastric ulcer treated with ranitidine plus triple therapy (bismuth subsalicylate, tetracycline and metronidazole) and 11 gastric ulcer patients treated with ranitidine alone [25] . The life table probability of ulcer recurrence one year after ulcer healing was significantly lower in the patients who had received ranitidine plus triple therapy (13 [26] . The 12-month gastric ulcer relapse rate was 51 percent in the patients who had received omeprazole compared to three percent in those who had been treated by triple therapy. In all of the above-mentioned studies, there was a striking relation between H. pylori eradication and absence of gastric ulcer recurrence. This relationship was confirmed by studies in which gastric ulcer patients treated by H. pylori eradication therapy regimens were divided into those with successful H. pylori eradication and those in whom the H. pylori eradication regimen had failed. Labenz et al. reported a one-year gastric ulcer recurrence rate of 58 percent (10/18) in patients with H. pylori persistence compared to three percent (1/32) in patients in whom H. pylori was eradicated from the stomach [21] . Similar results were reported by Seppala et al. who reported a one-year recurrence rate of 47 percent (60/128) and seven percent (2/29) in gastric ulcer patients after failed and successful H. pylori eradication, respectively [22] .
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND GASTRIC ULCER
NSAIDs are generally accepted to play a pathogenetic role in the development of gastric ulcer in patients taking such drugs. These ulcers are suggested to be secondary to the NSAID-induced reduction of gastric prostaglandins resulting in an impaired mucosal barrier against aggressive luminal factors, such as acid or pepsin. Interestingly, gastric ulcer may also occur during NSAID-use in patients with achlorhydria due to gastric atrophy [27] . This finding may be important in understanding the limited role of antisecretory drugs in NSAID-related gastric ulcer [28] . The contribution of H. pylori infection to the pathogenesis of gastric ulcer in patients taking NSAIDs is a matter of debate.
In an endoscopic study of patients with rheumatoid arthritis, five of 81 [29] were found to have a gastric ulcer. In the patients who were seropositive for H. pylori the gastric ulcer rate was five percent (3/55) compared to eight percent (2/26) in H. pylori seronegative patients with rheumatoid arthritis. Thus, gastric ulcer may occur in both H. pylori-positive and H. pylori-negative patients with rheumatoid arthritis. It has, however, been claimed that NSAIDs induce gastric ulcer mainly in H. pylori carriers. In patients with a history of NSAID use, H. pylori positivity was found in 21 of 27 (78 percent) gastric ulcer patients compared to 13 of 38 (34 percent) patients without an ulcer [30] . Furthermore, a recent study in healthy volunteers showed that severe gastric damage induced by NSAIDs was associated with H. pylori infection [31] .
Since the ulcerogenic effect of NSAIDs has been well established, this therapy should be discontinued in any patient with a gastric ulcer who is taking such drugs.
Continuing NSAID therapy is reported to lower the ulcer healing effect of antisecretory drugs. For example, 32 percent and 53 percent of NSAID-users compared to 59 percent and 85 percent of patients not taking NSAIDs had their gastric ulcer healed with 150 mg twice daily ranitidine at four and eight weeks, respectively [15] . However, the percentage of healed gastric ulcer with 40 mg/day omeprazole in patients receiving concurrent treatment with NSAIDs (81 percent at four weeks and 95 percent at eight weeks) was not different from that in patients who did not take NSAIDs (80 percent at four weeks and 96 percent at eight weeks) [15] . Thus, in patients who need continuous NSAID-therapy, powerful acid inhibitory therapy is required to heal gastric ulcer. It has not yet been established whether H. pylori eradication therapy accelerates gastric ulcer healing during continuous NSAID therapy. Clinically it is very difficult to determine whether a gastric ulcer in an H. pylori-positive patient with a history of NSAID use is related to the NSAID use, to the H. pylori-associated gastritis or to the combination of both factors. Since H. pylori eradication therapy largely prevents gastric ulcer recurrences, it seems logical to apply this therapy also to H. pylori positive gastric ulcer patients with chronic NSAID use.
However, the prophylactic effect of H. pylori eradication therapy in patients on continuing NSAID treatment has yet to be determined.
H. pylori-negative patients on chronic NSAID therapy who have a history of NSAIDinduced gastric ulcer are candidates for long-term prophylactic therapy. The efficacy of acid inhibitory therapy in the prevention of gastric ulcer in patients taking NSAIDs is limited. Preliminary studies suggest that powerful acid inhibitory therapy with high-dose H2RAs or proton pump inhibitors may be beneficial in such patients [32, 33] . Another approach is the long-term administration of prostaglandin analogues. Several studies have shown that the prostaglandin analogue misoprostol lowers the relapse rate of gastric ulcer in patients on chronic NSAID-therapy [8] [9] [10] 34] . However, side-effects (abdominal cramps, diarrhea) occur rather frequently and may hamper the application of this class of compounds.
CONCLUSION
The recent appreciation of the importance of H. pylori infection and of NSAID use has changed the medical management of patients with a gastric ulcer. By far the majority of patients will be effectively managed by one of the modalities of drug therapy. Surgery is to be restricted to gastric ulcer patients with complications, severe dysplasia and those who are not able or willing to take the medication.
